FierceBiotech21h
Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...
BioSpace15h
Upstream Raises $255M IPO for Inflammatory Drugs; CAMP4 Nets $75M for RNA Work
Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer ...
FierceBiotech4d
CAMP4 is latest biotech to eye IPO, while Upstream spells out $182M plans
RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...
devdiscourse16h
Health Highlights: IPOs, Pharma Deals, and Medical Advancements
This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a ...
Investing1d
Upstream’s IPO reflects strong investor interest in immune drug research
Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...
Upstream Bio Announces Pricing of Upsized Initial Public Offering
The gross proceeds to Upstream from the initial public offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $255.0 million. Registration ...